Gilead Sciences, Inc. (NASDAQ:GILD) Holdings Decreased by OLD National Bancorp IN

OLD National Bancorp IN lessened its stake in Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) by 30.8% in the first quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 12,030 shares of the biopharmaceutical company's stock after selling 5,365 shares during the quarter. OLD National Bancorp IN's holdings in Gilead Sciences were worth $1,348,000 at the end of the most recent quarter.

Other large investors have also made changes to their positions in the company. Bridgewater Associates LP grew its stake in Gilead Sciences by 122.7% in the 4th quarter. Bridgewater Associates LP now owns 460,936 shares of the biopharmaceutical company's stock valued at $42,577,000 after acquiring an additional 253,994 shares during the last quarter. Nissay Asset Management Corp Japan ADV boosted its stake in shares of Gilead Sciences by 5.2% during the 4th quarter. Nissay Asset Management Corp Japan ADV now owns 284,243 shares of the biopharmaceutical company's stock worth $26,750,000 after purchasing an additional 14,009 shares during the last quarter. Ontario Teachers Pension Plan Board boosted its stake in shares of Gilead Sciences by 54.6% during the 4th quarter. Ontario Teachers Pension Plan Board now owns 37,051 shares of the biopharmaceutical company's stock worth $3,422,000 after purchasing an additional 13,086 shares during the last quarter. Mufg Securities Americas Inc. acquired a new stake in shares of Gilead Sciences during the 4th quarter worth about $1,699,000. Finally, Convergence Investment Partners LLC boosted its position in shares of Gilead Sciences by 15.8% in the fourth quarter. Convergence Investment Partners LLC now owns 68,447 shares of the biopharmaceutical company's stock worth $6,322,000 after acquiring an additional 9,330 shares during the last quarter. Hedge funds and other institutional investors own 83.67% of the company's stock.

Insider Activity

In related news, CEO Daniel Patrick O'day sold 10,000 shares of Gilead Sciences stock in a transaction dated Friday, May 30th. The shares were sold at an average price of $110.42, for a total transaction of $1,104,200.00. Following the sale, the chief executive officer now directly owns 620,268 shares in the company, valued at $68,489,992.56. The trade was a 1.59% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, CFO Andrew D. Dickinson sold 2,500 shares of Gilead Sciences stock in a transaction dated Tuesday, April 15th. The shares were sold at an average price of $106.40, for a total transaction of $266,000.00. Following the sale, the chief financial officer now owns 168,174 shares in the company, valued at approximately $17,893,713.60. This represents a 1.46% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last quarter, insiders sold 43,000 shares of company stock valued at $4,630,310. 0.27% of the stock is currently owned by company insiders.

Gilead Sciences Stock Performance

Gilead Sciences stock traded down $2.07 during mid-day trading on Friday, reaching $109.98. The company's stock had a trading volume of 8,148,740 shares, compared to its average volume of 7,752,495. The firm has a market cap of $136.81 billion, a price-to-earnings ratio of 297.24, a PEG ratio of 0.71 and a beta of 0.29. The business has a 50 day moving average price of $105.54 and a 200-day moving average price of $102.06. The company has a current ratio of 1.50, a quick ratio of 1.20 and a debt-to-equity ratio of 1.24. Gilead Sciences, Inc. has a twelve month low of $62.69 and a twelve month high of $119.96.

Gilead Sciences (NASDAQ:GILD - Get Free Report) last released its quarterly earnings data on Thursday, April 24th. The biopharmaceutical company reported $1.81 EPS for the quarter, topping analysts' consensus estimates of $1.77 by $0.04. The firm had revenue of $6.67 billion during the quarter, compared to the consensus estimate of $6.77 billion. Gilead Sciences had a net margin of 1.67% and a return on equity of 31.63%. The firm's revenue was down .3% on a year-over-year basis. During the same quarter in the previous year, the company posted ($1.32) earnings per share. Sell-side analysts predict that Gilead Sciences, Inc. will post 7.95 EPS for the current fiscal year.

Gilead Sciences Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Friday, June 27th. Stockholders of record on Friday, June 13th will be issued a dividend of $0.79 per share. This represents a $3.16 annualized dividend and a dividend yield of 2.87%. The ex-dividend date of this dividend is Friday, June 13th. Gilead Sciences's dividend payout ratio (DPR) is 66.53%.

Analyst Ratings Changes

GILD has been the topic of several research analyst reports. Deutsche Bank Aktiengesellschaft raised shares of Gilead Sciences from a "hold" rating to a "buy" rating and raised their target price for the stock from $80.00 to $120.00 in a research report on Tuesday, February 18th. Wells Fargo & Company raised their price target on shares of Gilead Sciences from $120.00 to $140.00 and gave the company an "overweight" rating in a report on Wednesday, March 5th. DZ Bank upgraded shares of Gilead Sciences from a "hold" rating to a "buy" rating and set a $108.00 price target on the stock in a report on Thursday, February 13th. Cantor Fitzgerald assumed coverage on shares of Gilead Sciences in a report on Tuesday, April 22nd. They issued an "overweight" rating and a $125.00 price target on the stock. Finally, Morgan Stanley raised their price target on shares of Gilead Sciences from $130.00 to $135.00 and gave the company an "overweight" rating in a report on Friday, April 25th. Nine equities research analysts have rated the stock with a hold rating, fifteen have given a buy rating and three have assigned a strong buy rating to the company's stock. According to data from MarketBeat, the company has a consensus rating of "Moderate Buy" and a consensus target price of $110.55.

About Gilead Sciences

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.